Ryan Dittamore

CEO|Board member, liquid Bx, mol Dx, medtech, focused on developing products that improve health outcomes

[Ryan Dittamore @rdittamore]

@Dr_RaviMadan @theNCI @melissaabel20 @EdwinPosadasMD @RickLee6 @PCFnews @urotoday @DeborahCitrin @gulleyj1 @billdahutmd @RPachynski @apolo_andrea @PGrivasMDPhD Congrats on 21+ impactful years!

[Ryan Dittamore @rdittamore]

@maughanonc Congrats! Great to hear this news.

[Ryan Dittamore @rdittamore]

@UCSFUrology @SimaPorten @Uro_Max @ben_breyer Congrats Sima! Wonderful news.

[Ryan Dittamore @rdittamore]

@Kaochar2 @Bea0317Knudsen @PCF_Science Great to see, we had developed a CIN CTC morphology biomarkers that was quite prognostic back in the day. https://t.co/qigNzbYNWh

[Ryan Dittamore @rdittamore]

@ewanagibb @EurUrolOncol @JoepJdeJong @pcvblack @LDyrskjot Congrats @ewanagibb looking forward to reading more from your lab!

[Ryan Dittamore @rdittamore]

@DrSpratticus @NCCN @sandysrimd Congrats Dan! A perfect role for you.

[Ryan Dittamore @rdittamore]

Congrats @JoshLangMD and team, wonderful work and insights. Any comments on CTC heterogeneity and how CTC classes co-mingled and relationship to outcome? We always use to see high CTC heterogeneity at later lines of Rx and a link to poor prognosis and differentially worse outcome on AR tx vs taxane. For example saw pts with NE CTCs co-mingled with AR driven CTCs.

[Adam Feuerstein ✡️ @adamfeuerstein]

In this week's Biotech Scorecard newsletter:

MASH drugs have reached a meaningful tipping point for patients and investors.

$MDGL already topping $400 million in annualized sales.
$AKRO reversing cirrhosis in F4 patients + $ETNB following

It's taken a long time — a lot of ups and downs — but MASH is finally proving to be a massive opportunity. Really good to see.

[Misha Beltran @mishabeltran]

In memory of Dr. Felix Feng. Thank you @EUplatinum for honoring our beloved colleague and friend, gone too soon. We miss you Felix @MaryFengMD @nlinmd @PCF_Science

https://t.co/WOGllHwEfQ

[Ryan Dittamore @rdittamore]

@JoshLangMD I learned so much from @felixfengmd, mostly that some rare people just have an extra gear: in effort, in resilience, in intellegence, and in kindness. He was the best of us.

[Ryan Dittamore @rdittamore]

Wonderful overview by @ChenUltrasound on SonoBiopsy evolution enabling a non-invasive BBB opening for accessing molecular diagnosis for brain diseases @leuthardt @CordanceM #istu2024

[Ryan Dittamore @rdittamore]

@VanProstateCtr @ResearchWyatt Congrats @ResearchWyatt well deserved!

[Focused Ultrasound Foundation @FUSFoundation]

An article about focused ultrasound-induced blood-brain barrier (BBB) opening by Foundation Chairman Neal Kassell, MD, was recently published by @medicine_maker. The piece discusses how noninvasive focused ultrasound can safely and temporarily open the BBB and how the technology has the potential to transform the treatment of challenging neurodegenerative diseases like Alzheimer’s.
Access the article: https://t.co/bJRDASWk5t

[Ryan Dittamore @rdittamore]

@JoshLangMD @PCF_Science @uw_medicine @UWCarbone Congrats Josh. Well deserved!

[Ryan Dittamore @rdittamore]

Opening the blood-brain barrier will be non-invasive, portable and accessible. A great set of innovations and technology @CordanceM for our NeuroAccess platform https://t.co/aWTuV5gGjU

[Ryan Dittamore @rdittamore]

Great to go through @EFrontierLabs, a wonderful experience with some great mentors and students alike. @AlexJonsson_

[Endless Frontier Labs @EFrontierLabs]

.@PoetsAndQuants published a writeup featuring Endless Frontier Labs and our MBA alum, Alexander Jonsson, who nows work at @CordanceM (Deep Tech, '21-22 Cohort).

Learn more: https://t.co/f7pViLpi4K

[Ryan Dittamore @rdittamore]

@uroegg The reason why biomarkers (genomics and digital path) are so important, especially in community settings where Gleason grading can be widely variable.

[Ryan Dittamore @rdittamore]

A tremendous study. Can’t wait for the @CordanceM focused ultrasound device to be utilized in Alzheimer’s patients.

[Eric Topol @EricTopol]

A very recent @NEJM paper reviewed the use of focused ultrasound to the brain in 3 patients with Alzheimer's disease
https://t.co/7qUDL1OPVw
Now this is the focus of a @60Minutes segment

[Ryan Dittamore @rdittamore]

@JMaraganore I would suggest a few edits, the focus on large biotech/pharma as a training ground isn’t always best. A stint yes, but if they are interested in innovation a small company is a much better place to get exposure and experience. Also a top tier education isn’t essential.

[Ryan Dittamore @rdittamore]

Focused ultrasound facilitated BBB opening will be a critical part of Alzheimer’s therapy, more data needed but an exciting time @CordanceM

[NEJM @NEJM]

In three patients with Alzheimer’s disease, focused ultrasound was applied with aducanumab therapy. Reduction in amyloid was greater in treated regions than in matched contralateral regions over 6 months. Read the full report: https://t.co/qa4QdhznGK